Cancer Therapy News and Research

RSS

Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: Study

In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.

28 May 2010

Concord Medical first-quarter total net revenues increase 36.6% to $11.2 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2010.

27 May 2010

Use of bisphosphonates associated with risk of developing BON after dental surgery: Study

People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of The Journal of the American Dental Association.

27 May 2010

Blocking the activity of death receptor can stop tumor growth: New research study

Every cell contains machinery for self-destruction, used to induce death when damaged or sick. But according to a new research study, a receptor thought to mediate cell suicide in normal cells may actually be responsible for the unrestrained growth of cancerous tumors.

27 May 2010

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

Rensselaer Polytechnic Institute Professor Richard Radke is leading a new $1.4 million study to develop novel computer automation techniques that could reduce the prep time of a promising cancer-treatment technology from several hours to a few minutes.

27 May 2010

New book summarizes current state of research on NF-κB

NF-κB is a critical signaling molecule in the immune system that regulates cell survival and cell death, lymphocyte responses, and inflammation. Acting as a transcription factor that can receive several inputs, it coordinates distinct gene expression programs in response to a wide variety of stimuli.

26 May 2010

EMEND indication helps women prevent CINV

More women fighting cancers such as breast, lung, colorectal and ovarian can now help prevent the nausea and vomiting associated with their treatment of moderately emetogenic (vomit-inducing) cancer chemotherapy. Although new treatment entities have been developed in the past 10 years for control of chemically-induced nausea and vomiting, CINV remains a significant problem in the context of current practice.

26 May 2010

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC.

26 May 2010

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Eastern Idaho Regional Medical Center (EIRMC), a full-service regional medical center in Idaho Falls, and West Valley Medical Center, a community hospital in Caldwell, will continue to provide in-network medical care to all Medicare Advantage members enrolled in plans offered by Humana, under terms of a renewal agreement announced today.

26 May 2010

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

24 May 2010

State roundup: Genetic testing on campus, Texas docs in Mass., and more

"A plan by the University of California, Berkeley to voluntarily test the DNA of incoming freshman has come under fire from critics who said the school was pushing an unproven technology on impressionable students. The university has said it will send test kits to 5,500 new students to analyze genes that help control the body's responses to alcohol, dairy products and folic acid" (Wohlsen, 5/21).

24 May 2010

UAB Comprehensive Cancer Center commemorates signing of new act for cancer screening programs

The University of Alabama at Birmingham Comprehensive Cancer Center commemorated the signing of legislation requiring the Alabama Department of Public Health to create breast, cervical and colorectal cancer screening programs designed to save the lives of thousands of Alabamians in an event held May 19.

24 May 2010

New therapies can turn cancer into chronic disease

Two new studies suggest that the prolonged use of cancer drugs helped stunt the progress of the disease, a shift from the scheduled courses of treatment typically delivered to patients, The Wall Street Journal reports.

24 May 2010

New study reveals PTPN2 gene loss causes bone cancer

In patients with leukemia, the formation of white blood cells in the bone marrow is disrupted. This makes leukemia patients particularly susceptible to infections, because properly functioning white blood cells ensure protection against intruders such as viruses and bacteria.

21 May 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

20 May 2010

70% of oncologists and 60% of ob-gyns disagree with Task Force's mammogram recommendations

Recent recommendations by the US Preventive Task Force on Breast Cancer advising that women under the age of 50 should not get routine mammograms have resulted in fierce debate within the medical community. According to a new oncology study from ORC, an Infogroup Company, 70 percent of oncologists and 60 percent of ob-gyns disagree with the assertion that women should not get mammograms before the age of 50.

20 May 2010

Curis announces inclusion in NASDAQ Biotechnology Index

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI), which will become effective prior to market open on Monday, May 24, 2010.

19 May 2010

New DVS radiation measurement device for prostate cancer treatment

John Theurer Cancer Center at Hackensack University Medical Center announced today that it is one of two cancer centers in the tri-state area currently implanting a wireless radiation sensor, known as DVS. John Theurer Cancer Center radiation oncologists can now receive data immediately post- treatment on the precise amount of radiation being delivered to tumors and surrounding tissue for prostate cancer treatments.

18 May 2010

Sonablate HIFU treatment now available in Bermuda for patients with prostate cancer

US HIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies, is pleased to announce that its HIFU treatment for prostate cancer is now available in Bermuda. King Edward VII Memorial Hospital in Bermuda joins more than 100 centers in 30-plus countries to offer the innovative treatment with the Sonablate 500 medical device.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

Cancer Therapy News and Research

Positron Emission Mammography helps evaluate response to neoadjuvant chemotherapy: Study

Concord Medical first-quarter total net revenues increase 36.6% to $11.2 million

Use of bisphosphonates associated with risk of developing BON after dental surgery: Study

Blocking the activity of death receptor can stop tumor growth: New research study

New $1.4M study to develop novel computer automation techniques for reducing prep time of IMRT for cancer

New book summarizes current state of research on NF-κB

EMEND indication helps women prevent CINV

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

State roundup: Genetic testing on campus, Texas docs in Mass., and more

UAB Comprehensive Cancer Center commemorates signing of new act for cancer screening programs

New therapies can turn cancer into chronic disease

New study reveals PTPN2 gene loss causes bone cancer

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

70% of oncologists and 60% of ob-gyns disagree with Task Force's mammogram recommendations

Curis announces inclusion in NASDAQ Biotechnology Index

New DVS radiation measurement device for prostate cancer treatment

Sonablate HIFU treatment now available in Bermuda for patients with prostate cancer

152 research and training grants awarded to researchers at 93 institutions nationwide

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News